Similar articles for PMID: 33622764

Year	Number of Results
1953	1
2005	1
2006	1
2008	1
2010	2
2011	4
2012	1
2013	3
2014	8
2015	4
2016	4
2017	6
2018	15
2019	21
2020	24
2021	22
2022	6

1

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.

Eydt E, Glegg S, Sutherland C, Meador K, Trew M, Perreault M, Goyer MÈ, Le Foll B, Turnbull J, Fairbairn N. Eydt E, et al. CMAJ Open. 2021 Feb 23;9(1):E115-E124. doi: 10.9778/cmajo.20200021. Print 2021 Jan-Mar. CMAJ Open. 2021. PMID: 33622764 Free PMC article.

2

Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.

Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, Oviedo-Joekes E, Le Foll B, Goyer MÈ, Perreault M, Sutherland C. Fairbairn N, et al. CMAJ. 2019 Sep 23;191(38):E1049-E1056. doi: 10.1503/cmaj.190344. CMAJ. 2019. PMID: 31548191 Free PMC article. No abstract available.

3

Injectable opioid agonist treatment: An evolutionary concept analysis.

Haines M, O'Byrne P. Haines M, et al. Res Nurs Health. 2021 Aug;44(4):664-671. doi: 10.1002/nur.22140. Epub 2021 May 16. Res Nurs Health. 2021. PMID: 33993526

4

Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.

Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, Harrison S, Janmohamed A, Zhang DZ, Anis AH, Krausz M, Marsh DC, Schechter MT. Oviedo-Joekes E, et al. Drug Alcohol Depend. 2017 Jul 1;176:55-62. doi: 10.1016/j.drugalcdep.2017.02.021. Epub 2017 May 10. Drug Alcohol Depend. 2017. PMID: 28521199 Clinical Trial.

5

Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.

Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Harrison S, MacDonald S, Lock K, Anis AH, Marsh DC, Schechter MT. Oviedo-Joekes E, et al. J Subst Abuse Treat. 2019 Jun;101:50-54. doi: 10.1016/j.jsat.2019.03.012. Epub 2019 Apr 4. J Subst Abuse Treat. 2019. PMID: 31174713 Clinical Trial.

6

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.

Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Oviedo-Joekes E, et al. Subst Abuse Treat Prev Policy. 2021 Mar 5;16(1):22. doi: 10.1186/s13011-021-00358-x. Subst Abuse Treat Prev Policy. 2021. PMID: 33673847 Free PMC article.

7

Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.

Oviedo-Joekes E, Marsh DC, Guh D, Brissette S, Schechter MT. Oviedo-Joekes E, et al. J Opioid Manag. 2011 Sep-Oct;7(5):371-6. doi: 10.5055/jom.2011.0078. J Opioid Manag. 2011. PMID: 22165036 Clinical Trial.

8

Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder.

Brar R, Sutherland C, Nolan S. Brar R, et al. BMJ Case Rep. 2019 Aug 1;12(7):e229456. doi: 10.1136/bcr-2019-229456. BMJ Case Rep. 2019. PMID: 31371332 Free PMC article.

9

Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, Marsh DC, Schechter MT. Oviedo-Joekes E, et al. JAMA Psychiatry. 2016 May 1;73(5):447-55. doi: 10.1001/jamapsychiatry.2016.0109. JAMA Psychiatry. 2016. PMID: 27049826 Clinical Trial.

10

Use of a primary care and pharmacy-based model for the delivery of injectable opioid agonist treatment for severe opioid use disorder: a case report.

Wilson T, Brar R, Sutherland C, Nolan S. Wilson T, et al. CMAJ. 2020 Feb 3;192(5):E115-E117. doi: 10.1503/cmaj.190732. CMAJ. 2020. PMID: 32015080 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed